The insulin receptor negatively regulates the action of pseudomonas toxin-based immunotoxins and native pseudomonas toxin

Cancer Research

Volumn 73, Issue 7, 2013, Pages 2281-2288

  Liu, Xiu Fen ^a   FitzGerald, David J ^a   Pastan, Ira ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOHEXIMIDE; ELONGATION FACTOR 2; ETOPOSIDE; FURIN; IMMUNOTOXIN; INSULIN RECEPTOR; MESOTHELIN; MESOTHELIN FRAGMENT VARIABLE ANTIBODY PSEUDOMONAS EXOTOXIN A; MONOCLONAL ANTIBODY; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SPECIFICITY; GENE SILENCING; HUMAN; HUMAN CELL; INSULIN RECEPTOR GENE; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RECEPTOR GENE; REGULATORY MECHANISM; RNA INTERFERENCE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BACTERIAL TOXINS; BLOTTING, WESTERN; CELL PROLIFERATION; GPI-LINKED PROTEINS; HUMANS; IMMUNOTOXINS; MESOTHELIOMA; PSEUDOMONAS AERUGINOSA; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, INSULIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84875971904     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-3436     Document Type: Article

References (23)

1. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-57.
2. Wu AM, Senter PD. Arming antibodies: prospects and changes for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
3. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011;71:6300-9
4. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6:559-65.
5. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42.
6. Hassan R, Laszik ZG, Lerner M, Raffield M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124:838-45.
7. Weldon JE, Pastan I. Guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011;278:4683-700.
8. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kinderler H, Willingham MC, et al. Phase I study of SS1P, a recombinantanti-mesothelin immunotoxin givenasabolus I.V. infusiontopatientswith mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9.
9. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008;44:46-53.
10. Dupont J, Leroith D. Insulin and insulin-like growth factor I receptors: similarity and differences in signal transduction. Horm Res 2001; 55:22-6.
11. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006;7: 85-96.
12. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, et al. The role of insulin receptor and IGF-1 receptor in cancer and other disease. Arch Physiol Biochem 2008;114:23-37.
13. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. Methods Mol Biol 2004;248:503-18.
14. Du X, Youle RJ, Fitzgerald DJ, Pastan I. Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol Cell Biol 2010;30:3444-52.
15. Chiron MF, Fryling CM, Fitzgerald DJ. Furin-mediated cleavage of Pseudomonas exotoxin-derived chimeric toxins. J Biol Chem 1997;272:3107-11.
16. Spooner RA, Watson P. Drug targeting: learning from toxin entry and trafficking in mammalian cells. Curr Opin Drug Discov Devel 2010; 13:86-95.
17. Kao AW, Ceresa BP, Santeler SR, Pessin JE. Expression of a dominant interfering dynamin mutant in 3T3L1 adipocytes inhibits GLUT4 endocytosis without affecting insulin signaling. J Biol Chem 1998;273: 25450-7.
18. Bryant NJ, Govers R, James DE. Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 2002;4:267-77.
19. Boucher J, Macotela Y, Bezy O, Mori MA, Kriauciunas K, Kahn CR. A kinase-independent role of unoccupied insulin and IGF-1 receptors in the control of apoptosis. Sci Signal 2010;3:ra87.
20. Antonino B, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009; 30:586-623.
21. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414:799-806.
22. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, et al. Insulin receptor activation by IGF-II in breast cancer: evidence for a new autocrine/paracrine mechanism. Oncogene 1999;18: 2471-9.
23. Ulanet D, Ludwig D, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci USA 2010; 107:10791-8.